NCT04541654

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,500 (estimated)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).

Detailed description

This research study looks to enroll as many people with LFS or TP53 gene variants as possible in order to: * Better estimate cancer risks in individuals with TP53 variants or LFS, which is a rare condition. * Learn the range of cancer risks linked to TP53 variants to help individuals and families to improve our ability to counsel patients and families about cancer risks more accurately. * Improve opportunities for cancer prevention, early detection, and treatment. * Learn more about the meaning of TP53 variants in the blood that are not inherited (e.g. ACE/CHIP and mosaicism). Study procedures will include: * Collecting information from the participant's medical record and short questionnaires. * Collecting blood, saliva, eyebrow hair and tumor tissue samples (optional). * Sharing study information with family members (optional). It is expected that about 1500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent. The National Cancer Institute is providing funding for part of this study and is considered a study sponsor. They will require that some of the genetic information be made available to the research community without personal identifying information.

Conditions

• Li-Fraumeni Syndrome
• TP53 Gene Mutation
• Hereditary Cancer Syndrome
• Clonal Hematopoiesis
• Mosaicism

Interventions

Type	Name	Description
GENETIC	Data and Specimen Collection	* Provide research team and access to relevant medical records * Answer short questionnaires periodically * Consider consenting to other optional parts of the research such as: * Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional). * Provide a saliva sample (optional). * Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional). * Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional). * Consider inviting relatives to join the study (optional).

Timeline

• Start date: 2020-09-15
• Primary completion: 2030-12-31
• Completion: 2032-12-31
• First posted: 2020-09-09
• Last updated: 2026-03-27

Locations

3 sites across 1 country: United States